These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 21247815)

  • 1. [Potential risks of the adverse effects of thyrotropin suppression in differentiated thyroid carcinoma].
    Reverter JL; Colomé E
    Endocrinol Nutr; 2011 Feb; 58(2):75-83. PubMed ID: 21247815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical endocrinologists' perception of the deleterious effects of TSH suppressive therapy in patients with differentiated thyroid carcinoma].
    Reverter JL; Colomé E; Puig Domingo M; Julián T; Halperin I; Sanmartí A
    Endocrinol Nutr; 2010 Oct; 57(8):350-6. PubMed ID: 20494634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of short-term metformin therapy associated with levothyroxine dose decrement on TSH and thyroid hormone levels in patients with thyroid cancer.
    Mousavi Z; Dourandish L; Rokni H; Sadeghi R; Rasoul Zakavi S
    Minerva Endocrinol; 2014 Mar; 39(1):59-65. PubMed ID: 24513605
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thyrotropin suppression and disease progression in patients with differentiated thyroid cancer: results from the National Thyroid Cancer Treatment Cooperative Registry.
    Cooper DS; Specker B; Ho M; Sperling M; Ladenson PW; Ross DS; Ain KB; Bigos ST; Brierley JD; Haugen BR; Klein I; Robbins J; Sherman SI; Taylor T; Maxon HR
    Thyroid; 1998 Sep; 8(9):737-44. PubMed ID: 9777742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bone mineral density in patients receiving suppressive doses of thyroxine for thyroid carcinoma.
    Florkowski CM; Brownlie BE; Elliot JR; Ayling EM; Turner JG
    N Z Med J; 1993 Oct; 106(966):443-4. PubMed ID: 8233173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk-benefit ratio for TSH- suppressive Levothyroxine therapy in differentiated thyroid cancer.
    Do Cao C; Wémeau JL
    Ann Endocrinol (Paris); 2015 Feb; 76(1 Suppl 1):1S47-52. PubMed ID: 26826483
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low trabecular bone score in postmenopausal women with differentiated thyroid carcinoma after long-term TSH suppressive therapy.
    De Mingo Dominguez ML; Guadalix Iglesias S; Martin-Arriscado Arroba C; López Alvarez B; Martínez Diaz-Guerra G; Martinez-Pueyo JI; Ferrero Herrero E; Hawkins Carranza F
    Endocrine; 2018 Oct; 62(1):166-173. PubMed ID: 30014437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Altered bioavailability due to changes in the formulation of a commercial preparation of levothyroxine in patients with differentiated thyroid carcinoma.
    Olveira G; Almaraz MC; Soriguer F; Garriga MJ; Gonzalez-Romero S; Tinahones F; Ruiz de Adana MS
    Clin Endocrinol (Oxf); 1997 Jun; 46(6):707-11. PubMed ID: 9274701
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of UGT1A1, UGT1A3, DIO1 and DIO2 polymorphisms on L-thyroxine doses required for TSH suppression in patients with differentiated thyroid cancer.
    Santoro AB; Vargens DD; Barros Filho Mde C; Bulzico DA; Kowalski LP; Meirelles RM; Paula DP; Neves RR; Pessoa CN; Struchine CJ; Suarez-Kurtz G
    Br J Clin Pharmacol; 2014 Nov; 78(5):1067-75. PubMed ID: 24910925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thyroid Hormone Suppression Therapy.
    Biondi B; Cooper DS
    Endocrinol Metab Clin North Am; 2019 Mar; 48(1):227-237. PubMed ID: 30717904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Hormonal therapy in differentiated carcinoma of the thyroid gland].
    Francia G; Davì MV; Petroziello A; Sussi PL
    Chir Ital; 1994; 46(4):56-8. PubMed ID: 7882445
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of Chronic Suppression or Oversuppression of Thyroid-Stimulating Hormone on Psychological Symptoms and Sleep Quality in Patients with Differentiated Thyroid Cancer.
    Altuntaş SÇ; Hocaoğlu Ç
    Horm Metab Res; 2021 Oct; 53(10):683-691. PubMed ID: 34607367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Benefits of thyrotropin suppression versus the risks of adverse effects in differentiated thyroid cancer.
    Biondi B; Cooper DS
    Thyroid; 2010 Feb; 20(2):135-46. PubMed ID: 20151821
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronic thyrotropin-suppressive therapy with levothyroxine and short-term overt hypothyroidism after thyroxine withdrawal are associated with undesirable cardiovascular effects in patients with differentiated thyroid carcinoma.
    Botella-Carretero JI; Gómez-Bueno M; Barrios V; Caballero C; García-Robles R; Sancho J; Escobar-Morreale HF
    Endocr Relat Cancer; 2004 Jun; 11(2):345-56. PubMed ID: 15163309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of quantitative measurement of thyroglobulin mRNA in the follow-up of differentiated thyroid cancer.
    Denizot A; Delfino C; Dutour-Meyer A; Fina F; Ouafik L
    Thyroid; 2003 Sep; 13(9):867-72. PubMed ID: 14588101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of postoperative thyrotropin suppressive therapy on bone mineral density in patients with papillary thyroid carcinoma: a prospective controlled study.
    Sugitani I; Fujimoto Y
    Surgery; 2011 Dec; 150(6):1250-7. PubMed ID: 22136848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thyroid-stimulating hormone suppression therapy for differentiated thyroid cancer: The role for a combined T3/T4 approach.
    Fussey JM; Khan H; Ahsan F; Prashant R; Pettit L
    Head Neck; 2017 Dec; 39(12):2567-2572. PubMed ID: 28960722
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Increase in TSH levels in thyroid carcinoma patients after withdrawal of suppressive levothyroxine medication].
    Hackländer S; Voth E; Schicha H
    Nuklearmedizin; 1996 Oct; 35(5):170-4. PubMed ID: 9005413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Highly sensitive determination of TSH in the follow-up of TSH-suppressive therapy of patients with differentiated thyroid cancer.
    Mann K; Saller B; Mehl U; Hörmann R; Moser E
    Nuklearmedizin; 1988 Feb; 27(1):24-8. PubMed ID: 3368333
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Three-week thyroxine withdrawal thyroglobulin stimulation screening test to detect low-risk residual/recurrent well-differentiated thyroid carcinoma.
    Golger A; Fridman TR; Eski S; Witterick IJ; Freeman JL; Walfish PG
    J Endocrinol Invest; 2003 Oct; 26(10):1023-31. PubMed ID: 14759077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.